A Non-Interventional, Prospective Study to Assess Seizure Control and Tolerability of Eslicarbazepine Acetate as Adjunctive Therapy to One Baseline Antiepileptic Drug, in Adults With Partial-Onset Seizures With or Without Secondary Generalization.

Trial Profile

A Non-Interventional, Prospective Study to Assess Seizure Control and Tolerability of Eslicarbazepine Acetate as Adjunctive Therapy to One Baseline Antiepileptic Drug, in Adults With Partial-Onset Seizures With or Without Secondary Generalization.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Jan 2017

At a glance

  • Drugs Eslicarbazepine acetate (Primary) ; Antiepileptic drugs
  • Indications Partial epilepsies
  • Focus Therapeutic Use
  • Acronyms ESLADOBA
  • Sponsors Bial
  • Most Recent Events

    • 05 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 04 Dec 2016 Results presented at the American Epilepsy Society (AES) as per Eisai Co Ltd media release.
    • 04 Dec 2016 Results published in a Eisai Co Ltd media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top